Advancing Antibody Therapeutics for Inflammatory and Immune-Driven Diseases
Elemental Biologics is a biotechnology company developing monoclonal antibody therapies for immune-driven diseases involving chronic inflammation and immune dysregulation. These include autoimmune, inflammatory, and fibrotic diseases, as well as age-related inflammatory conditions with significant unmet medical need.
Elemental Biologics identifies immune pathways that are relevant across multiple related diseases. We apply advanced antibody engineering and translationally relevant preclinical models to generate specific, developable therapeutic candidates.
By targeting shared biological mechanisms, our strategy supports focused development with broader and scalable therapeutic potential.
Elemental Biologics is advancing multiple monoclonal antibody programs guided by strategic target selection and a disciplined development approach. Together, these programs demonstrate the robustness of our antibody discovery platform.
Elemental Biologics welcomes engagement with investors, strategic partners, and collaborators aligned with our scientific focus.